Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOHN W. who wrote (3191)	12/7/1997 4:48:00 PM
From: Peter Silsbee	Read Replies (3) of 6136

>> At 12 weeks, patients taking 141W94 at the highest dose, 1200mg twice daily, plus Retrovir(R) (AZT) and Epivir(R) (3TC) had a median 2.65 log reduction in viral load (greater than 99.8%) from baseline as compared to a 1.33 log reduction for the control arm, Retrovir(R) and Epivir(R). At 12 weeks, approximately 70 percent of patients across all 141W94 dose groups experienced drops in HIV viral load to below the limits of detection... It is certainly possible, as someone has mentioned, that the higher-dose group had numbers significantly better than 70 percent. But, if this is the case, why wouldn't that be in the release? Others at SI have taught me to view this sort of "selective" release of information as at least a small red flag. VRTX claims to have a drug "at least as potent or more potent...." What would be their reason for not supporting this statement with some clinical data? PLS

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next